

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## SINO BIOPHARMACEUTICAL LIMITED

中國生物製藥有限公司

*(Incorporated in the Cayman Islands with limited liability)*

*Website: [www.sinobiopharm.com](http://www.sinobiopharm.com)*

**(Stock code: 1177)**

### **RESIGNATION OF EXECUTIVE DIRECTOR AND CHANGE OF CHIEF EXECUTIVE OFFICER**

The Board announces that Mr. Xu Xiaoyang has tendered his resignation as an executive director, a member of the Executive Board Committee and the Chief Executive Officer of the Company, with effect from 31 July 2016.

Mr. Tse Ping, an executive director of the Company, has been appointed as the Chief Executive Officer of the Company, with effect from 31 July 2016.

#### **RESIGNATION OF EXECUTIVE DIRECTOR AND CHIEF EXECUTIVE OFFICER**

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, collectively the “**Group**”) announces that Mr. Xu Xiaoyang (“**Mr. Xu**”) has tendered his resignation as an executive director, a member of the Executive Board Committee and the Chief Executive Officer of the Company, in order to focus on his other business and personal commitments, with effect from 31 July 2016.

Mr. Xu has confirmed that he has no disagreement with the Board and that there are no matters which need to be brought to the attention of the Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) or the shareholders of the Company in relation to his resignation.

The Board would like to take this opportunity to express its sincere gratitude to Mr. Xu for his invaluable contribution made to the Company during his tenure of office.

#### **APPOINTMENT OF CHIEF EXECUTIVE OFFICER**

Following Mr. Xu’s resignation, Mr. Tse Ping (“**Mr. Tse**”), an executive director of the Company, has been appointed as the Chief Executive Officer of the Company, with effect from 31 July 2016.

Mr. Tse is the founder of the Group and has more than 23 years of experience in the investment and management in pharmaceutical industry in China, having been steering the Group's reform and innovation and robust growth. The Board would also like to extend its best wishes to Mr. Tse for his new role, wishing that under the leadership of Mr. Tse, the Group can further strengthen its core competitiveness in the enlarged healthcare fields and achieve greater success.

The biographical details of Mr. Tse can be found on the website ([www. sinobiopharm.com](http://www.sinobiopharm.com)) and in the 2015 annual report of the Company. Mr. Tse has not held any directorship in any other listed companies in the last three years preceding the date of this announcement. He is the father of Miss Tse, Theresa Y Y, the Chairman of the Board, and the first cousin of Mr. Tse Hsin, a director of the Company. Other than that, he does not have any relationship with any directors and substantial or controlling shareholders of the Company.

As at the date of this announcement, Mr. Tse holds 1,222,526,722 shares of the Company through his own interest and interest in Validated Profits Limited. He also holds 288,000,000 shares of Beijing Tide Pharmaceutical Co. Ltd. through his interest in controlled corporations. Save as disclosed above, Mr. Tse does not have any interest or short position in shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance.

Save as disclosed above, there is no further information to be disclosed pursuant to the requirements of Rule 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on the Stock Exchange and there is no other matter relating to the appointment of Mr. Tse as the Chief Executive Officer of the Company that needs to be brought to the attention of the shareholders of the Company.

By Order of the Board  
**Sino Biopharmaceutical Limited**  
**Tse, Theresa Y Y**  
*Chairlady*

Hong Kong, 29 July 2016

*As at the date of this announcement, the Board comprises seven executive directors, namely Miss Tse, Theresa Y Y, Mr. Tse Ping, Mr. Xu Xiaoyang, Mr. Tse Hsin, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and four independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong and Mr. Zhang Lu Fu.*